One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD

Phase 1positiveCPV-104Positive

AI Analysis

Summary

One04 Therapeutics launched with encouraging Phase 1 interim results for CPV-104 and plans to expand clinical development into kidney diseases and dry age-related macular degeneration.

Clinical Trial Data

Phase

Phase 1

Outcome Details

encouraging interim results

Importance:5/10

Sentiment:

0.70

Phase 1CPV-104kidney diseasedry AMDclinical developmentcompany launch

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 6:33 AM

Read Original